. The recognition of the links between the coagulation system and the immune response [5, 8] 
Sepsis is a life-threatening clinical syndrome that arises through the innate response to infection
, and can appear as a complication of trauma, cancer or major elective surgery [2] [3] (Fig. 1) [6, 7] . The recognition of the links between the coagulation system and the immune response [5, 8] [10] . Reperfusion in a variety of organs triggers production of acute-phase proteins (e.g. CRP), a second round of pro-inflammatory mediators and activates defence mechanisms such as the complement system, leading to widespread deposition of complement complexes in the microcirculation [11] . While during early stages of sepsis complement is an important defence mechanism, helping to clear invading bacteria; however, complement activation ultimately contributes to and amplifies the IR injury during late stages [12] . Complement split products (C3a and C5a) enhance cytokine and chemokine production, elicit leucocyte chemotaxis and activation, promote ROS generation and adhesion molecule expression [13] .
advanced the understanding sepsis pathophysiology and led to the development of the only specific anti-sepsis treatment currently available, recombinant human activated protein C (APC) produced and marketed by Eli Lilly (Indianapolis, IN, USA) as Xigris®. While early restoration of blood flow to ischaemic tissue is essential to halt the progression of cellular injury associated with decreased oxygen and nutrient delivery, late reperfusion of ischaemic tissue initiates a series of detrimental reactions, broadly named ischaemia-reperfusion (IR) injury [9]. This is a result of intense inflammation and oxidative damage induced by ROS, nitrogen metabolites and inflammatory leucocytes
Currently, sepsis therapy is mainly limited to measures directed at its infectious causes (e.g. antibiotics, surgical and supportive therapies) rather than modifying the pathophysiologic processes responsible for its initiation and progression [14] 
